Journal
CANCER LETTERS
Volume 330, Issue 1, Pages 84-95Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.11.032
Keywords
AC133; Cancer stem cell; CD133; RNA aptamer; SELEX; Therapeutic
Categories
Funding
- Australia-India Strategic Research Fund [ST010013]
- Victorian Cancer Agency [PTCP-02]
- Career Development and Support Fellowship Future Research Leader Grant of the NSW Cancer Institute, Australia [08/FRL/1-04]
Ask authors/readers for more resources
The monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface marker of cancer stem cells in several different cancer types. Here, we describe the isolation and characterisation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell targeted therapeutics and molecular imaging. Crown Copyright (C) 2012 Published by Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
